Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients

Pediatric Transplantation

Volumn 13, Issue 1, 2009, Pages 54-62

  Schubert, S ^a   Abdul Khaliq, H ^b   Lehmkuhl, H B ^a   Yegitbasi, M ^a   Reinke, P ^c   Kebelmann Betzig, C ^c   Hauptmann, K ^c   Gross Wieltsch, U ^d   Hetzer, R ^a   Berger, F ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d OLGAHOSPITAL   (Germany)

Author keywords

Epstein Barr virus; Maintenance immunosuppression; PCR; Pediatric heart transplant; Post transplant lymphoproliferative disease; T lymphocytes

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; THYMOCYTE ANTIBODY;

ARTICLE; B CELL LYMPHOMA; BLOOD GROUP RH; BURKITT LYMPHOMA; CARDIAC GRAFT REJECTION; CHILD; CHILD CARE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FOLLOW UP; HEART GRAFT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; T CELL LYMPHOMA; VIRUS INFECTION;

CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; HEART TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES;

EID: 58149308122     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00969.x     Document Type: Article

References (45)

1. Mendoza F, Kunitake H, Laks H, et al. Post-transplant lymphoproliferative disorder following pediatric heart transplantation. Pediatr Transplant 2006 : 10 : 60 66.
2. Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): Current perspectives. Semin Thorac Cardiovasc Surg 1996 : 8 : 139 148.
3. Cohen AH, Sweet SC, Mendeloff E, et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2000 : 161 : 1252 1255.
4. Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003 : 22 : 505 514.
5. Shroff R, Rees L. The post-transplant lymphoproliferative disorder - a literature review. Pediatr Nephrol 2004 : 19 : 369 377.
6. Cao S, Cox K, Esquivel CO, et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation 1998 : 66 : 851 856.
7. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001 : 71 : 1065 1068.
8. Ross M, Kouretas P, Gamberg P, et al. Ten- and 20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung Transplant 2006 : 25 : 261 270.
9. Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): A single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005 : 24 : 671 679.
10. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999 : 67 : 990 998.
11. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002 : 159 : 9 18.
12. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997 : 14 : 8 14.
13. Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transpl Infect Dis 2001 : 3 : 88 96.
14. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998 : 16 : 2052 2059.
15. Merlino C, Cavallo R, Bergallo M, et al. Quantitative PCR in EBV-infected renal transplant patients. New Microbiol 2001 : 24 : 223 229.
16. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001 : 97 : 1165 1171.
17. Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998 : 17 : 1161 1166.
18. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997 : 2 : 33 40.
19. Schubert S, Renner C, Hammer M, et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008 : 27 : 100 105.
20. Lamy ME, Favart AM, Cornu C, et al. Epstein-Barr virus infection in 59 orthotopic liver transplant patients. Med Microbiol Immunol (Berl) 1990 : 179 : 137 144.
21. Aalto SM, Linnavuori K, Peltola H, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998 : 56 : 186 191.
22. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005 : 80 : 1233 1243.
23. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003 : 76 : 984 988.
24. Grambsch P, Louis TA, Bostick RM, et al. Statistical analysis of proliferative index data in clinical trials. Stat Med 1994 : 13 : 1619 1634.
25. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004 : 78 : 1676 1682.
26. Wasson S, Zafar MN, Best J, et al. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: A single-center experience. J Cardiovasc Pharmacol Ther 2006 : 11 : 77 83.
27. Allen UD, Farkas G, Hebert D, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatr Transplant 2005 : 9 : 450 455.
28. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997 : 176 : 1462 1467.
29. Riebel T, Kebelmann-Betzing C, Scheer I. Ultrasound in abdominal and soft-tissue childhood PTLD (post-transplant lymphoproliferative disease). Ultraschall Med 2007 : 28 : 201 205.
30. Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncol 2007 : 24 : 125 136.
31. Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007 : 41 : 1648 1659.
32. El-Salem M, Raghunath PN, Marzec M, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest 2007 : 87 : 29 39.
33. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006 : 6 : 2735 2742.
34. Dharnidharka V. Dual monoclonal antibody therapy for the treatment of PTLD? Pediatr Transplant 2003 : 7 : 337 338.
35. Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005 : 9 : 622 626.
36. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003 : 75 : 1710 1717.
37. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 2005 : 9 : 520 522.
38. Salaman J. Cyclosporine mono-drug therapy. Transplant Proc 1988 : 20 : 117 120.
39. Sherritt MA, Bharadwaj M, Burrows JM, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003 : 75 : 1556 1560.
40. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006 : 6 : 569 576.
41. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002 : 99 : 2592 2598.
42. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). Blood 2006 : 108 : 2942 2949.
43. Verschuuren EA, Stevens SJ, Van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: The remission, the relapse, and the complication. Transplantation 2002 : 73 : 100 104.
44. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005 : 5 : 566 572.
45. Bakker NA, Van Imhoff GW, Verschuuren EA, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005 : 19 : 327 334.